30-Day Clinical Outcomes of a Self-Expanding Transcatheter Aortic Valve
JACC: Cardiovascular Interventions · 2023-03 · 16 (6) · 681-689
DOI: 10.1016/j.jcin.2023.02.002 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift JACC: Cardiovascular Interventions, 2023-03. Verfasst von Michael J Reardon und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: mreardon@houstonm…. Hauptthemen laut MEDLINE: Aortic Valve Stenosis, Transcatheter Aortic Valve Replacement, Heart Valve Prosthesis. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 14 Literaturangaben. Gefördert von: Abbott Laboratories.
Abstract (Originalsprache)
BACKGROUND: The self-expanding, intra-annular Navitor (Abbott Structural Heart) valve includes an outer cuff to reduce paravalvular leak (PVL) and large stent cells for future coronary access. OBJECTIVES: The purpose of the PORTICO NG (Evaluation of the Portico NG [Next Generation] Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis) study is to evaluate the safety and effectiveness of the Navitor valve in patients with symptomatic, severe aortic stenosis who are at high or extreme surgical risk. METHODS: PORTICO NG is a prospective, multicenter, global study with follow-up at 30 days, 1 year, and annually through 5 years. The primary endpoints are all-cause mortality and moderate or greater PVL at 30 days. Valve Academic Research Consortium-2 events and valve performance are assessed by an independent clinical events committee and echocardiographic core laboratory. RESULTS: A total of 260 subjects were treated at 26 clinical sites across Europe, Australia, and the United States between September 2019 and August 2022. The mean age was 83.4 ± 5.4 years, 57.3% were female, and the average Society of Thoracic Surgeons score was 3.9% ± 2.1%. At 30 days, the rate of all-cause mortality was 1.9%, and no subjects had moderate or greater PVL. The rate of disabling stroke was 1.9%, life-threatening bleeding was 3.8%, stage 3 acute kidney injury was 0.8%, major vascular complications were 4.2%, and new permanent pacemaker implantation was 19.0%. Hemodynamic performance included a mean gradient of 7.4 ± 3.5 mm Hg and an effective orifice area of 2.00 ± 0.47 cm2. CONCLUSIONS: The Navitor valve is safe and effective for the treatment of subjects with severe aortic stenosis who are at high or greater risk for surgery, which is supported by low rates of adverse events and PVL. (Evaluation of the Portico NG [Next Generation] Transcatheter Aortic Valve in High and Extreme Risk Patients With Symptomatic Severe Aortic Stenosis [PORTICO NG]; NCT04011722).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Surgery, Houston Methodist DeBakey Heart and Vascular Center, Houston, Texas, USA. Electronic address: mreardon@houstonmethodist.org.
- Department of Cardiology, Ascension Via Christi Hospital, University of Kansas, Wichita, Kansas, USA.
- Morriston Hospital, Swansea Bay University Health Board, Swansea, United Kingdom.
- Department of Interventional Cardiology, Alfred Hospital, Melbourne, Victoria, Australia; Monash University, Melbourne, Victoria, Australia.
- Department of Cardiology, Macquarie University Hospital, New South Wales, Australia.
- Regional Cardiology Centre, Royal Victoria Hospital, Belfast, United Kingdom.
Förderung
- Abbott Laboratories
Zitieren
APA
Reardon, M. J., Chehab, B., Smith, D., Walton, A. S., Worthley, S. G., Manoharan, G., Sultan, I., Yong, G., Harrington, K., Mahoney, P., Kleiman, N., Makkar, R. R., Fontana, G., DeLago, A., Ramana, R. K., Bates, N., & Søndergaard, L. (2023). 30-Day Clinical Outcomes of a Self-Expanding Transcatheter Aortic Valve. JACC: Cardiovascular Interventions, 16(6), 681-689. https://doi.org/10.1016/j.jcin.2023.02.002
Vancouver
Reardon MJ, Chehab B, Smith D, Walton AS, Worthley SG, Manoharan G, et al. 30-Day Clinical Outcomes of a Self-Expanding Transcatheter Aortic Valve. JACC: Cardiovascular Interventions. 2023;16(6):681-689. doi:10.1016/j.jcin.2023.02.002
BibTeX
@article{Reardon2023,
author = {Reardon, Michael J and Chehab, Bassem and Smith, Dave and Walton, Antony S and Worthley, Stephen G and Manoharan, Ganesh and Sultan, Ibrahim and Yong, Gerald and Harrington, Katherine and Mahoney, Paul and Kleiman, Neal and Makkar, Raj R and Fontana, Gregory and DeLago, Augustin and Ramana, Ravi K and Bates, Nicholas and Søndergaard, Lars},
title = {30-Day Clinical Outcomes of a Self-Expanding Transcatheter Aortic Valve},
journal = {JACC: Cardiovascular Interventions},
year = {2023},
volume = {16},
number = {6},
pages = {681--689},
doi = {10.1016/j.jcin.2023.02.002}
}
EUVIMED